Physician

Sidharth Bagga, MD, MBA

According to 2025 Medicare claims, Sidharth Bagga, MD, MBA (NPI: 1285865436) practices internal medicine in the Chico, CA market, with the plurality of this provider's patient population coming from Butte, CA. This provider's primary affiliated billing organization is OROHEALTH CORPORATION A NON PROFIT HEALTHCARE SYSTEM (NPI: 1013933167; TIN: 942994776) and primary practice location at 95966-6118.

Bagga's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 630 traditional Medicare patients, billed 4,900 HCPCS/CPT codes, and received $451,546 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 9,900 prescription claims across 1,200 beneficiaries totaling $2,706,584 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 9,090 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $132,445 to $451,546. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $435,354 to $2,706,584. For DME billing, reported payments moved from a lower plateau to a higher plateau, from $258,929 to $718,448.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	668	1,566	$132,445
2016	866	2,981	$227,261
2017	1,180	5,161	$421,293
2018	1,444	8,279	$578,972
2019	1,249	5,541	$416,948
2020	619	3,167	$388,239
2021	691	5,396	$558,231
2022	700	5,896	$573,280
2023	696	5,120	$497,945
2024	630	4,900	$451,546

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	273	1,478	$435,354
2016	285	1,674	$628,937
2017	454	2,446	$724,977
2018	602	4,211	$1,135,677
2019	829	6,468	$1,762,831
2020	1,041	9,687	$2,606,135
2021	1,199	10,672	$3,325,900
2022	1,254	11,254	$3,759,295
2023	1,170	10,243	$3,416,827
2024	1,200	9,900	$2,706,584

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	733	3,498	$295,862
2016	891	4,294	$261,055
2017	1,047	4,386	$229,853
2018	1,533	6,578	$370,940
2019	2,211	8,603	$550,944
2020	2,590	10,569	$857,582
2021	2,711	10,798	$947,757
2022	2,549	10,734	$1,011,033
2023	2,344	10,451	$1,090,698
2024	2,262	9,090	$866,619

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	418	541	$132
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	124	147	$101
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	441	2,346	$92
31624	Irrigation and suction of lung airways to obtain cells using an endoscope	271	328	$89
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	307	644	$61

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	895	30,510	$620,915
Spiriva Respimat	Tiotropium Bromide	616	20,903	$352,728
Prolastin C	Alpha-1-Proteinase Inhibitor	20	560	$242,632
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	402	14,610	$212,060
Breo Ellipta	Fluticasone/Vilanterol	397	13,648	$172,534

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0466	Home ventilator, any type, used with non-invasive interface, (e.g., mask, chest shell)	Y	54	458	$388,327
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	265	2,012	$136,205
J7677	Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram	N	15	120	$104,582
J7606	Formoterol fumarate, inhalation solution, fda approved final product, non-compounded, administered through dme, unit dose form, 20 micrograms	N	26	140	$22,243
E0465	Home ventilator, any type, used with invasive interface, (e.g., tracheostomy tube)	Y	N/R	17	$19,094

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Sidharth Bagga, MD, MBA?

Tedicare shows public-source Medicare data for Sidharth Bagga, MD, MBA (NPI 1285865436), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sidharth Bagga, MD, MBA have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sidharth Bagga, MD, MBA?

Sidharth Bagga, MD, MBA is linked to OROHEALTH CORPORATION A NON PROFIT HEALTHCARE SYSTEM (billing NPI 1013933167) in the available physician profile data.

Does Sidharth Bagga, MD, MBA have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.